scholarly journals Contralateral Renal Cell Carcinoma Ureteric Metastases Can Arise on Tyrosine Kinase Adjuvant Therapy and Be Effectively Treated by Endoscopic Laser Excision and Ablation

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Sarah L. Reid ◽  
Nikolas J. Arestis ◽  
Craig McIlhenny ◽  
Gavin W. A. Lamb
Keyword(s):  
Renal Cell Carcinoma ◽  
Local Recurrence ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
The Other ◽  
Renal Unit ◽  
Endoscopic Laser ◽  
Laser Excision ◽  
Work Up ◽  
Synchronous Lesion

Renal cell carcinoma (RCC) uncommonly metastasizes to the ureter and rarely to the contralateral ureter. We describe the presentation of 2 successive contralateral ureteric metastases from RCC in our institution. The first represents the only reported metachronous ureteric deposit on adjuvant sorafenib after laparoscopic radical nephrectomy for RCC. The other presented with a synchronous lesion after radiological work-up. Both lesions were treated with endoscopic excision and laser ablation with preservation of the renal unit and no local recurrence. We report these cases and discuss the literature.

Distinguishing splenosis from local recurrence of renal cell carcinoma using a technetium sulfur colloid scan

2007 ◽  
Vol 14 (3) ◽  
pp. 245-247 ◽  
Author(s):  
Susumu Umemoto ◽  
Yasuhide Miyoshi ◽  
Noboru Nakaigawa ◽  
Masahiro Yao ◽  
Shigeo Takebayashi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Local Recurrence ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Sulfur Colloid

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.

1990 ◽  
Vol 8 (3) ◽  
pp. 460-467 ◽  
Author(s):  
R L Krigel ◽  
K A Padavic-Shaller ◽  
A R Rudolph ◽  
M Konrad ◽  
E C Bradley ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Local Recurrence ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Nk Cell ◽  
Objective Response ◽  
Interleukin 2 ◽  
Cell Activity ◽  
Nk Cell Activity ◽  
Beta Interferon

Preclinical data have demonstrated synergy between interleukin-2 (IL-2) and beta-interferon (IFN-beta) in stimulating natural-killer (NK) cell activity and in increasing expression of IL-2 receptors. Based on results of a phase I trial, a combination of IL-2 and IFN-beta was administered three times weekly by intravenous (IV) bolus injection with 5 x 10(6) Cetus U/m2 of IL-2 and 6 x 10(6) U/m2 of IFN-beta to 24 patients with advanced renal cell carcinoma (RCC). Of 22 assessable patients there were six (27%) objective responses including one complete remission (CR) and five partial responses (PRs). There were three minor responses (MRs), 11 stable disease (SD), and two progressive disease (PD). Two of the objective responses have continued for almost 2 years. Response sites include lymph nodes, lungs, and bone. Toxicities requiring dose reduction include arthralgia, weight loss, fatigue, decreased performance status, depression, and hypotension. Five of 10 patients who had a prior nephrectomy without local recurrence achieved an objective response as compared with only one of 12 without a prior nephrectomy or with a local recurrence (P = .04). Mean peak lymphokine-activated killer (LAK) cell activity of the objective responders was 88 lytic units (LU) as compared with 4 LU in the nonresponders (P = .01). Mean peak NK cell activity was 288 LU in the objective responders as compared with 100 LU in the nonresponders (P = .10).(ABSTRACT TRUNCATED AT 250 WORDS)

Bowel Intussusception Caused by a Single Clear Cell Renal Cell Carcinoma Metastasis

1998 ◽  
Vol 65 (4) ◽  
pp. 574-575
Author(s):  
B. Chertin ◽  
E. Feigin ◽  
L Rivkin ◽  
C. Reinus ◽  
O. Lernau ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Bowel Wall ◽  
Cell Renal Cell Carcinoma ◽  
Small Bowel Intussusception ◽  
Renal Cell Carcinoma Metastasis ◽  
Carcinoma Metastasis ◽  
Work Up ◽  
Similar Kind

A 70-year-old white woman presented with small bowel intussusception due to metastasis of renal cell carcinoma (RCC) acting as a leading point. The patient had undergone nephrectomy seven years previously. Metastatic work-up showed no additional metastases. Only three previously publicized cases of a similar kind were found. Intussusception brought about by a metastasis to the bowel wall is rare, but should be borne in mind.

scholarly journals Efficacy of povidone-iodine against accidental tumor incision during nephron-sparing surgery: experimental study in patients with renal cell carcinoma

2019 ◽  
Vol 47 (10) ◽  
pp. 4993-5002
Author(s):  
Gang Li ◽  
Chao Zhi ◽  
Dongsheng Zhu ◽  
Zihao Liu ◽  
Yuanjie Niu
Keyword(s):  
Renal Cell Carcinoma ◽  
Local Recurrence ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Renal Cell ◽  
Povidone Iodine ◽  
Nephron Sparing Surgery ◽  
In Vitro Experiments ◽  
Nephron Sparing

Purpose Accidental tumor incision (ATI) can occur during nephron-sparing surgery (NSS) and correlates with recurrence and metastasis. This study investigated risk factors of intraoperative ATI in renal cell carcinoma (RCC) patients after NSS and the efficacy of povidone-iodine for ATI. Methods A retrospective analysis was performed on 150 consecutive stage I (pT1N0M0) RCC patients who underwent NSS at The Second Hospital of Tianjin Medical University between May 2010 and October 2015 for the causes of ATI. Furthermore, in vitro experiments investigated whether tumor cells remained on the surface of scissors and the effect of treatment with povidone-iodine on the number of remaining 786-O cells. Results Among the 150 cases, 15 showed ATI, of which three suffered local recurrence during a median follow-up of 56 months. Pseudocapsules, satellite nodules, and renal cystic tumors were observed in ATI cases. In vitro experiments showed that tumor cells remained on the surface of scissors after ATI during NSS and that 0.5% povidone-iodine effectively killed tumor cells in 30 minutes. Conclusions The probability of ATI is high in patients with complex-type RCC during NSS. ATI potentially increases the chance of metastasis and local recurrence, and 0.5% povidone-iodine kills tumor cells more effectively than distilled water.

Examination of genomic copy number alterations in renal cell carcinoma with sarcomatoid features.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 478-478
Author(s):  
Timothy Ito ◽  
Jianming Pei ◽  
Essel Dulaimi ◽  
Craig Menges ◽  
Philip Abbosh ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Copy Number ◽  
Genetic Alterations ◽  
The Other ◽  
Copy Number Alterations ◽  
Genomic Copy Number ◽  
Genomic Copy ◽  
Sarcomatoid Differentiation

478 Background: Sarcomatoid differentiation is an uncommon histological finding in renal cell carcinoma (RCC) that may develop from any RCC subtype and is associated with a very poor prognosis. The identification of genetic alterations that drive this aggressive phenotype could aid in the development of more effective targeted therapies. In this study, we aimed to identify unique copy number alterations (CNAs) in patients with sarcomatoid RCC when compared to those with other RCC subtypes. Methods: Genomic copy number analysis was performed using single nucleotide polymorphism (SNP)-based microarrays on tissue extracted from the tumors of 80 patients (9 with sarcomatoid features (sRCC), 39 clear cell (ccRCC), 26 papillary (pRCC) and 6 chromophobe RCC (chRCC)) who underwent renal mass excision between 2010 - 2014. Statistical analysis was performed using Kaplan Meier (KM) survival analysis, t-tests and Fisher exact tests where appropriate. Results: sRCC tumors exhibited significantly higher numbers of CNAs when compared to ccRCC, pRCC and chRCC (mean 20.1 vs. 6.6 vs. 7.0 vs. 6.3, respectively; p <0.0001). The most common copy number losses occurred in chromosome arms 1p, 3p, 9q, 15q, 18q, 21q, and 22q, with losses of 9q (88%), 15q (77%), 18q (66%), and 22 (77%) being unique among sRCC tumors when compared to the other 3 histologies. The most common copy number gains were in chromosome arms 1q, 8q, 17q, and 20p/q, with 1q (55%) and 8q (66%) gains unique when compared to the other 3 histologies. Of the sRCC tumors, 3 arose from ccRCC, 2 from pRCC and 4 from unclassified RCC. sRCC was associated with worse survival compared to ccRCC, pRCC and chRCC on KM analysis (p=0.0006), and higher rates of lymph node positivity (77% vs. 3% vs. 12% vs. 0%, respectively; p<0.0001) and metastases (100% vs. 13% vs. 4% vs. 0%, respectively; p<0.0001) on presentation were observed with sRCC. Conclusions: Sarcomatoid differentiation in RCC is associated with a high rate of chromosomal changes with unique copy number alterations including losses of 9q, 15q, 18q and 22q and gains of 1q and 8q. Identification and validation of candidate driver genes or tumor suppressor loci within these chromosomal regions may help identify targets for future therapies.

Sign in / Sign up

Export Citation Format

Share Document